| Name | Title | Contact Details |
|---|
Cellartis AB is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aldevron provides contract manufacturing and scientific services. We specialize in plasmid DNA, protein production, and antibody generation. PLASMID DNA PRODUCTION With the successful completion of over 50,000 projects, we have developed unsurpassed expertise in plasmid manufacturing. Using proprietary technology, Aldevron manufactures DNA for a wide range of research, preclinical, clinical, and diagnostic applications (1 mg to 100 g). PROTEIN PRODUCTION Aldevron offers a wide range of protein services including host cell optimization, expression screening, process development, contract production, enzyme and antibody assay design, and more. Proteins produced by Aldevron are used for a wide range of agriculture and biomedical applications from research grade to full cGMP. ANTIBODY GENERATION GENOVAC Antibody Technology supports all project types from reagent antibodies to diagnostic and therapeutic applications with high success rates. Based on many years of experience, our immunization technology has been developed to cater for all protein targets where other methods have failed (including e.g. GPCRs). Our custom antibodies have been validated in over 130 publications and patents for more than 500 clients worldwide. Additional services include antibody processing, production, labeling, characterization and sequencing.
Molecular Therapeutics is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amyloid diseases are a diverse group of disorders, characterized by the deposition of amyloid protein fibrils in vital organs and tissues. There are approximately 30 different types of amyloidosis, each resulting from the misfolding and aggregation of a specific protein, and they are all severely debilitating, progressive, and often fatal.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. -We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses. -We are creating a new biopharmaceutical category for autoimmunity. We leverage a transformational drug development strategy that sources, repositions and advances candidates that: -Target the interception or prevention of immune-mediated disease -Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons -Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.